Preparation of the all-in-one CRISPR-Cas9/gRNA plasmid DNA was performed as described previously (Ran et al., 2013 (
link)). Briefly, the
single complementary DNA oligonucleotides corresponding to the gRNA sequence were commercially synthesized (Integrated DNA Technologies). After phosphorylation and annealing, the paired double strand DNA oligo was cloned into the BbsI linearized plasmid p
SpCas9(BB)-2A-GFP. Positive clones containing the gRNA-encoded DNA sequences were confirmed by DNA sequencing. For EC-specific genomic editing, the
CAG promoter in p
SpCas9(BB)-2A-GFP plasmid (CRISPR
CAG) was replaced with the human
CDH5 promoter (Gory et al., 1999 (
link)) using Kpn I and Age I restriction enzyme sites (CRISPR
CDH5). All gRNA sequences are listed in
Table S1.
To generate CRISPR
CDH5 plasmid expressing both
Pik3cg gRNA and FOXM1, the P2A and FOXM1 cDNA fragment was inserted into BsrGI linearized CRISPR
CDH5 plasmid DNA expressing
Pik3cg gRNA using
NEBuilder HiFi DNA assembly (New England Biolabs).
Dual targeting CRISPR plasmid DNA expressing
Pik3cg gRNA and
Vegfr2 gRNA was generated by inserting cassette of U6-Vegfr2 gRNA into CRISPR
CDH5 plasmid DNA expressing
Pik3cg gRNA using Xba I and Kpn I sites. All plasmids were confirmed by DNA sequencing.
Zhang X., Jin H., Huang X., Chaurasiya B., Dong D., Shanley T.P, & Zhao Y.Y. (2022). Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA. Cell reports, 38(1), 110196.